This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
GE HealthCare has purchased full ownership of Japanese radiopharmaceutical developer Nihon Medi-Physics (NMP) from Sumitomo Chemical. The deal, which was initially announced at RSNA 2024 , is expected to be neutral to GE HealthCare's adjusted earnings per share in the first year and accretive thereafter, according to the vendor.
GE HealthCare plans to launch its Flyrcado (flurpiridaz F-18) injection in the U.S. GE HealthCare's launch coincides with the receipt of pass-through status by the Centers for Medicare & Medicaid Services (CMS), effectiveApril 1st. The company received approval from the U.S.
Nucleus RadioPharma will use the money to establish manufacturing facilities—with one located in Rochester, Minnesota, near Mayo—and build new technology for distribution.
GE HealthCare plans to launch its Flyrcado (flurpiridaz F-18) injection in the U.S. GE HealthCare's launch coincides with the receipt of pass-through status by the Centers for Medicare & Medicaid Services (CMS), effectiveApril 1st. The company received approval from the U.S.
These SSTRs can be targeted both with gallium-68 (Ga-68) imaging agents and therapeutic lutetium-177 (Lu-177) radiopharmaceuticals using a so-called theranostics approach. healthcare setting, they wrote. In the U.S., The full article is available here.
Under the new policy, CMS will unpackage and pay separately for diagnostic radiopharmaceuticals with per-day costs exceeding $630, removing financial barriers that have long hindered patient access to essential nuclear medicine diagnostic procedures. tim.hodson Thu, 11/07/2024 - 11:25 Nov. Your voices made a difference.”
Additionally, modalities like MRI, CT, bone scans, and PET-CT are significant contributors to greenhouse gas emissions, with radiology accounting for approximately 1% of global healthcare-related emissions. SPECT and low-dose CT scans could be added for areas with suspected radiopharmaceutical uptake. hours), followed by DL1 (0.37 0.05
The Care Innovation Hub builds on a decades-long history between UCSF and GE HealthCare, bringing research focus areas under one framework. Together, were accelerating innovation in ways that will improve access to care and outcomes across healthcare settings. tim.hodson Mon, 01/27/2025 - 10:11 Jan.
Beyder played a key role in launching the radiopharmaceutical therapy (RPT) comprehensive center of excellence at WU, BJH, and Siteman Cancer Center last year. Looking back, he said a family promise led him into healthcare, and whether intentional about it or not, he's been ambitious to better healthcare since coming to the U.S.
In Brazil, the growing radiopharmaceutical market, driven by chronic disease and advanced imaging technologies, is becoming increasingly significant in healthcare. The post Advancing Healthcare: The Dynamic Growth of Brazil’s Radiopharmaceutical Market appeared first on Open Medscience.
With therapeutic radiopharmaceuticals coming to market quickly and available to smaller institutions around the U.S., My vision of a theranostic center includes a flagship facility that has a PET/CT scanner, a SPECT/CT scanner, and then multiple rooms for infusions of radiopharmaceuticals," Siegel explained.
AdvaMed currently counts approximately 450 companies as members and represents all aspects of medical technology. “Imaging is such an important component of [medical technology] in the healthcare system and it just makes a lot of sense for those companies to align their work here,” Whitaker told AuntMinnie.com.
5, 2025 Serac Healthcare Ltd., David Hail, Chief Executive of Serac Healthcare, commented, "We are delighted with the outcome of our End of Phase II Meeting with the FDA which provides us with a clear development path for maraciclatide. tim.hodson Wed, 02/05/2025 - 09:56 Feb.
The clinical trial will use this investigational radiopharmaceutical to help understand if patients have CD8+ T cells in their tumors and will, therefore, be more likely to respond to immune checkpoint inhibitors, the main class of immunotherapies currently approved for use.
Nucleus RadioPharma has secured $56 million in a Series A funding round to expand production of radiopharmaceutical treatments for cancer patients. Other investors included Echo Global, Fox Chase Cancer Center, Granger Management, Mayo Clinic, Mercy Health, and the University of Missouri.
Beyder played a key role in launching the radiopharmaceutical therapy (RPT) comprehensive center of excellence at WU, BJH, and Siteman Cancer Center last year. He then received his master's degree in public administration, with a focus on health policy, management, and international healthcare, from the New York University Robert F.
milla1cf Tue, 04/02/2024 - 18:51 April 2, 2024 — Less than three months after signing an agreement to acquire MIM Software Inc. , GE HealthCare Technologies Inc. This includes continuing to grow MIM Software’s offerings for end-to-end standardization across large healthcare system fleets.
GE HealthCare has signed an agreement with Axim Life Isotopes South Africa (Pty) Ltd. GE HealthCare will deliver the Cyclotrons to ALISA’s laboratory facility in Midrand, South Africa early next year, giving patients in Africa access to medical advancements.
milla1cf Wed, 10/11/2023 - 13:24 October 11, 2023 — GE HealthCare today announced an exclusive global licensing agreement with SOFIE Biosciences (SOFIE), a Virginia, U.S.-based SOFIE and GE HealthCare will collaborate on both the development and commercialization processes through a joint steering committee. Sherly Mosessian , Ph.D,
In response, GE HealthCare is proud to announce the development of its new MINItrace Magni, designed to be a small footprint, cost effective cyclotron for reliable, in-house production of commercial PET tracers and radiometals – like Gallium-68 – through solid target technology.
He has more than 22 years of operational and commercial expertise in radioisotopes and radiopharmaceuticals. actinium-225 (Ac-225), and drive business development initiatives for NorthStar’s Radiopharmaceutical CDMO/CMO business units. Ac-225 and Cu-67 using environmentally preferable technologies. Francis in Joliet, Ill.,
Marco Campione brings more than 25 years of experience from GE HealthCare, where he most recently served as Executive Director and Global Head of Contrast Media, General Manager Pharmaceutical Diagnostics North America and President GE HealthCare Inc., Campione also joins the Blue Earth Diagnostics Ltd. Bracco Imaging S.p.A.,
milla1cf Fri, 04/05/2024 - 11:31 April 5, 2024 — RLS Radiopharmacies , America’s only Joint Commission-accredited radiopharmacy network, today announced it has expanded its radiopharmaceutical contract development and manufacturing (rCDMO) capabilities by entering into a strategic agreement with global isotope technology leader Eckert & Ziegler.
milla1cf Mon, 06/19/2023 - 19:27 June 19, 2023 — NorthStar Medical Technologies, LLC , a global innovator in the development, production and commercialization of radiopharmaceuticals used for therapeutic applications and medical imaging, today announced the appointment of Frank Scholz, Ph.D., NorthStar’s commercialized, U.S.-based
Mr. Merrick continued, “Demand for therapeutic radiopharmaceuticals is increasing rapidly. NorthStar has further deepened and broadened our business platform with the recent establishment of a full-scale radiopharmaceutical CDMO/CMO services unit. Ac-225 using advanced, environmentally preferable electron accelerator technology.
This collaboration is a significant step forward in our mission to support healthcare providers and patients by providing high-quality medical isotopes. This agreement could be instrumental to the radiopharmaceutical industry and patient health.
milla1cf Mon, 04/24/2023 - 14:10 April 24, 2023 — - NorthStar Medical Radioisotopes , LLC, a global innovator in the development, production and commercialization of radiopharmaceuticals used for therapeutic and medical imaging applications, has announced the appointment of Jean-Noel David , MBA, MS, as Vice President, Operations.
Joining forces with CNL provides us the opportunity to extend our therapeutic portfolio as we continue striving to meet the needs of healthcare professionals and cancer patients worldwide,” commented Steffen Schuster , CEO of ITM. Targeted radiopharmaceuticals are created by linking a therapeutic radioisotope to a targeting molecule (e.g.,
SCINTIX therapy is a cutting-edge radiopharmaceutical-directed treatment applicable for early and late-stage cancers that uses the individual biology of each tumor to drive its own treatment. “We founder and CTO of RefleXion.
The PET/CT scanners will support the practice of theranostics , which enables clinicians to diagnose some forms of cancer with one radiopharmaceutical and treat the disease with a similar therapeutic agent.
As SNMMI president-elect, I plan to focus on bringing and integrating radiopharmaceutical theranostics into the clinic to benefit as many patients as possible," Urbain said in an SNMMI announcement. Jean-Luc Urbain, MD, PhD. “As
Life Molecular, a subsidiary of Life Healthcare Group, will complete the Phase 1/2a dose escalation study in collaboration with Lantheus. mtaschetta-millane Fri, 07/05/2024 - 06:00 July 5, 2024 — Lantheus Holdings, Inc. , This expands our therapeutic offerings and opens avenues for commercial synergies.”
milla1cf Thu, 11/02/2023 - 13:52 November 2, 2023 — GE HealthCare’s Artificial Intelligence ( AI ) models predict patient response to immunotherapies with 70 to 80 percent accuracy [1] , based on a pan-cancer cohort, according to findings to be presented at the Society for Immunotherapy of Cancer ( SITC ) in San Diego, U.S.,
For example, they use radiopharmaceuticals like Lutetium-177 to target and treat advanced prostate cancer or neuroendocrine tumors, providing personalized care for complex cases. They also lead the field in theranostics , which combines diagnostics and therapy in one procedure.
The post The Role of the Medical Gamma Camera in Modern Healthcare appeared first on Open MedScience. The gamma camera allows non-invasive imaging, enabling detailed diagnosis and monitoring of various medical conditions with precision.
As Theranostics and the use of radiopharmaceutical therapy (RPT) to treat cancer and other diseases have become more prevalent, interest in using dosimetry to personalize RPT treatments has grown. Dosimetry in Radiopharmaceutical Therapy. J Nucl Med. 2022 Oct;63(10):1467-1474. doi: 10.2967/jnumed.121.262305. 121.262305. [ii]
By the end of June 2023, commercial production across the country will be underway at the 31 PETNET radiopharmacies Blue Earth Diagnostics included in its New Drug Application for POSLUMA, marking a record number of sites authorized for the manufacturing of a radiopharmaceutical upon its initial FDA approval.
Weight loss medications are transforming healthcare, challenging medical devices, reshaping obesity treatment, and redefining patient outcomes globally. The post Weight Loss Medications Transform Healthcare Medical Device Giants appeared first on Open MedScience.
The post Medical Science Liaison: Bridging Science and Medicine for Better Healthcare appeared first on Open MedScience. What is a Medical Science Liaison? A professional who connects science and medicine through expert knowledge sharing.
The Digirad acquisition continues the expansion of TTG’s footprint across the country, notably on the West Coast, and adds to the breadth and experience that enable TTG to deliver a differentiated solution to a wide variety of healthcare providers.
We aim to provide the highest quality equipment and service and to deliver value to our customers through turnkey staffing and radiopharmaceutical solutions in our end-to-end model. Through organic growth, key partnerships, and targeted acquisitions, TTG delivers solutions to a broad continuum of healthcare providers within the United States.
commercial supply, Blue Earth is committed to make our new product widely available for patients and their physicians.” “The NCCN Guidelines are widely used by clinicians and healthcare providers as a benchmark to assess clinical utility,” said Eugene J. In conjunction with our continuing efforts to increase U.S.
Through organic growth, key partnerships, and targeted acquisitions, TTG delivers solutions to a broad continuum of healthcare providers within the United States. About TTG Imaging Solutions TTG Imaging Solutions provides a breadth of product and service offerings with its End-to-End Solution.
We organize all of the trending information in your field so you don't have to. Join 5,000 users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content